Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Janc

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Patients With Relapsed/Refractory T-Cell Lymphoma

Hematological Oncology

English

Related publications

DUAL PI3K Δ/Γ INHIBITOR RP6530 IN PATIENTS WITH RELAPSED/REFRACTORY T-Cell LYMPHOMA: DOSE ESCALATION FINDINGS.

Hematological Oncology

English

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

English

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (Aitl) and Cxcl12+ Peripheral T-Cell Lymphoma (Ptcl): Preliminary Results From a Phase 2 Study

Hematological Oncology

English

Correction To: Multicenter Phase 1/2 Study of Forodesine in Patients With Relapsed Peripheral T Cell Lymphoma

English

Outcome of Patients With Relapsed and Refractory Peripheral T Cell Lymphoma Intended for Stem Cell Transplant

Hematological Oncology

English

Sintilimab for Relapsed/Refractory (R/R) Extranodal Nk/T Cell Lymphoma (Enktl): A Multicenter, Single-Arm, Phase 2 Trial (Orient-4)

Hematological Oncology

English

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

Journal of Biological Chemistry

English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Janc

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Patients With Relapsed/Refractory T-Cell Lymphoma

Related publications

DUAL PI3K Δ/Γ INHIBITOR RP6530 IN PATIENTS WITH RELAPSED/REFRACTORY T-Cell LYMPHOMA: DOSE ESCALATION FINDINGS.

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (Aitl) and Cxcl12+ Peripheral T-Cell Lymphoma (Ptcl): Preliminary Results From a Phase 2 Study

Correction To: Multicenter Phase 1/2 Study of Forodesine in Patients With Relapsed Peripheral T Cell Lymphoma

Outcome of Patients With Relapsed and Refractory Peripheral T Cell Lymphoma Intended for Stem Cell Transplant

Sintilimab for Relapsed/Refractory (R/R) Extranodal Nk/T Cell Lymphoma (Enktl): A Multicenter, Single-Arm, Phase 2 Trial (Orient-4)

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma